The Molecular Cytogenetics Shared Resource (MCSR) has been in development over the last three years and was formally established as a shared resource in September 2003 to provide a wide range of cytogenetic services and investigations to the OSUCCC research community. It provides state-of-the-art molecular cytogenetic technology as well as classical banded metaphase cytogenetics. Services include metaphase karyotyping of human and mouse tissue, fluorescence in situ hybridization (FISH) using many different types of probes and tissues and multicolor spectral karyotyping (SKY). Dr. Heerema, Director of the Resource, brings a wealth of experience to the MCSR with over 25 years of experience in cytogenetics and over 135 publications. Dr. Mrozek, Associate Director of the Resource, has over 20 years of experience in cytogenetics and over 80 publications. Various specimen sources, such as human and mouse cell lines and tumor samples, paraffin embedded tissues and bone marrow or blood smears are studied, dependent on the purpose of the investigation. Services accommodate different stages of sample preparation from processing fresh tissues to preparing slides from fixed cell suspensions. Probes for FISH studies include both commercially available probes and probes developed by the MCSR. Probe development offerings include growth, amplification and labeling of the probes with different fluorophores available. The types of probes include unique-sequence DNA probes, BACs, PACs and YACs. The MCSR has been widely used by the OSUCCC research community. The projects vary from karyotyping cell lines to development of FISH probes (including probes specific for canine chromosomes), identification of appropriate samples to test the probes and performing FISH on cell lines and archived specimens. From inception to date, 15 OSUCCC members have used the MCSR for 24 different projects representing all six OSUCCC programs and requiring over 2,000 hours of usage. Tools used have included SKY analysis of cell lines and patient samples, G-banded karyotyping of mouse and human tumors and various cell lines, FISH using several different probes and tissues for hybridization as well as development and labeling of some of the probes. An additional 22 projects have been identified for future service. Maintenance of high-standards, establishment and proper use of controls and control values and careful monitoring of all phases of investigation assure quality. It is expected that future use of the MCSR will continue to be extensive, as investigators have indicated continuing need for the services offered.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-34
Application #
7743479
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2010-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$130,223
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kim, Miriam Y; Yu, Kyung-Rok; Kenderian, Saad S et al. (2018) Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell 173:1439-1453.e19
Malpeli, Giorgio; Barbi, Stefano; Tosadori, Gabriele et al. (2018) MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. Oncotarget 9:29753-29771
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Sharpnack, Michael F; Chen, Bin; Aran, Dvir et al. (2018) Global Transcriptome Analysis of RNA Abundance Regulation by ADAR in Lung Adenocarcinoma. EBioMedicine 27:167-175
Tanaka, Ichidai; Sato, Mitsuo; Kato, Toshio et al. (2018) eIF2?, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci 109:1843-1852
Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314
Bassett, Emily A; Palanichamy, Kamalakannan; Pearson, Mitchell et al. (2018) Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. Oncotarget 9:14597-14607
Trn?ný, Marek; Verhoef, Gregor; Dyer, Martin Js et al. (2018) A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica 103:1351-1358
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Long, Nicholas E; Sullivan, Brandon J; Ding, Haiming et al. (2018) Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging. J Biol Chem 293:9030-9040

Showing the most recent 10 out of 2602 publications